BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
McKinsey
Harvard Business School
Express Scripts
Julphar
Deloitte
Cipla
Dow
Fish and Richardson
Colorcon

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,492,416

« Back to Dashboard

Summary for Patent: 8,492,416
Title:2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
Abstract: The invention concerns 2-oxo-1-pyrrolidine derivatives of formula I, ##STR00001## wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals. The compounds of the invention are particularly suited for treating neurological disorders such as epilepsy.
Inventor(s): Kenda; Beno t (Emines, BE), Pasau; Patrick (Chastre, BE), Lallemand; Benedicte (Namur, BE)
Assignee: UCB Pharma, S.A. (Brussels, BE)
Application Number:13/222,477
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,492,416

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Ucb Inc BRIVIACT brivaracetam SOLUTION;INTRAVENOUS 205837-001 May 12, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ucb Inc BRIVIACT brivaracetam SOLUTION;INTRAVENOUS 205837-001 May 12, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY ➤ Subscribe
Ucb Inc BRIVIACT brivaracetam SOLUTION;ORAL 205838-001 May 12, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ucb Inc BRIVIACT brivaracetam SOLUTION;ORAL 205838-001 May 12, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY ➤ Subscribe
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-001 May 12, 2016 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY ➤ Subscribe
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-001 May 12, 2016 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-002 May 12, 2016 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-002 May 12, 2016 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY ➤ Subscribe
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-003 May 12, 2016 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY ➤ Subscribe
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-003 May 12, 2016 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,492,416

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0004297.8Feb 23, 2000

Non-Orange Book US Patents Family Members for Patent 8,492,416

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,911,461 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses ➤ Subscribe
6,713,635 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses ➤ Subscribe
7,358,276 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses ➤ Subscribe
6,784,197 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses ➤ Subscribe
6,969,770 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses ➤ Subscribe
6,858,740 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses ➤ Subscribe
6,806,287 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses ➤ Subscribe
8,034,958 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses ➤ Subscribe
7,217,826 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses ➤ Subscribe
7,692,028 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,492,416

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan 200626545 ➤ Subscribe
Taiwan 200626544 ➤ Subscribe
Slovenia 1265862 ➤ Subscribe
Saudi Arabia 1463 ➤ Subscribe
Saudi Arabia 1275 ➤ Subscribe
Russian Federation 2005125645 ➤ Subscribe
Russian Federation 2005125569 ➤ Subscribe
Russian Federation 2355680 ➤ Subscribe
Russian Federation 2006125756 ➤ Subscribe
Russian Federation 2292336 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Citi
QuintilesIMS
Harvard Business School
Merck
Colorcon
Queensland Health
Novartis
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot